Physician profile
Devin Reed
NPI 1497451470
$1,202.94
in general payments reported to CMS, 2019-2025
15 companies · $547 in 2025
The $547 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.63 · 2023: $191 · 2024: $447 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $345.75 | 2023-2025 | Versacross Access Solution, Farapulse, Watchman Flx |
| Abbvie INC. | $335.94 | 2023-2025 | |
| Amgen INC. | $162.28 | 2023-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $104.14 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $71.03 | 2023-2025 | Mounjaro, Zepbound |
| Organon LLC | $33.45 | 2024 | |
| Astellas Pharma US INC | $18.70 | 2024 | Veozah |
| Medtronic, INC. | $18.63 | 2022 | |
| Exact Sciences Corporation | $18.23 | 2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $18.23 | 2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.66 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $16.62 | 2025 | |
| Neurocrine Biosciences, INC. | $14.80 | 2023 | Ingrezza |
| Corcept Therapeutics | $14.56 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $13.92 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.